Onconetix, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Onconetix, Inc. on May 19, 2026. The filing details a corporate action approved by stockholders at a special meeting on April 30, 2026, and finalized by the Board of Directors on May 8, 2026.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. The primary financial metric disclosed is the reduction in outstanding common stock from approximately 11.4 million shares to approximately 1.14 million shares following the reverse stock split.
Material Changes
- Reverse Stock Split: The Board fixed a 1-for-10 reverse stock split ratio. Every 10 shares of common stock will convert into 1 share.
- Effective Date: The split is scheduled to become effective at 12:01 a.m. Eastern Time on May 21, 2026.
- Trading Adjustments: Trading will resume on a split-adjusted basis on May 21, 2026, under the symbol ONCO with a new CUSIP number (68237Q 401).
- Fractional Shares: No fractional shares will be issued; holders entitled to fractions will receive a cash payment based on the closing price on May 20, 2026.
- Equity Adjustments: Proportional adjustments will be made to exercise prices and share counts for equity awards, convertible preferred stock, and warrants.
Outlook, Risks, and Management Commentary
The primary purpose of the reverse stock split is to bring the Company into compliance with The Nasdaq Stock Market, LLC's minimum bid price requirements. The filing notes that the action will not alter any stockholder's percentage interest in the Company's equity, except for the rounding of fractional shares.
Investor Verification Checklist
- Verify the new CUSIP number (68237Q 401) with your brokerage to ensure proper trading on May 21, 2026.
- Confirm the treatment of fractional shares and the specific cash payment calculation if applicable to your holdings.
- Review the impact of the split on the exercise price and share count of any outstanding options, warrants, or convertible securities.
- Monitor the stock price post-split to ensure compliance with Nasdaq minimum bid price rules is maintained.